CJC-1295 No-DAC vs Tesamorelin

CJC-1295 No-DAC is a tetrasubstituted GHRH(1-29) analogue without DAC. Tesamorelin is a modified GHRH(1-44) analogue with an N-terminal trans-3-hexenoyl group. These are different structural approaches within the same catalog class.

Sequence substitutions and an N-terminal modification should not be treated as the same stabilization mechanism. Each compound's experimental exposure and response require evidence for that compound, and DAC-variant results cannot be transferred to the No-DAC preparation.

CJC-1295 No-DAC: CJC-1295 No-DAC is a tetrasubstituted analog of the 1-29 fragment of growth hormone-releasing hormone, without the albumin affinity complex. In preclinical models, it binds to the GHRH receptor and acts as an agonist of that pathway in the anterior pituitary. It has been investigated in models of somatotropic axis signaling in rodent studies.

Tesamorelin: Tesamorelin is a stabilized analog of the 44-amino-acid human growth hormone-releasing hormone, modified with a trans-3-hexenoyl group at the N-terminus. In research models, it binds to the GHRH receptor in the anterior pituitary and acts on that signaling pathway. It has been studied in models of the somatotropic axis and adipose tissue distribution in preclinical research.

CJC-1295 No-DAC: Substitutions at positions 2, 8, 15 and 27 reduce enzymatic degradation of the sequence in in vitro studies. Activation of the GHRH receptor increases cyclic AMP in cellular models.

Tesamorelin: The GHRH receptor is a Gs protein-coupled receptor whose activation increases intracellular cyclic AMP in cellular models. The N-terminal modification reduces enzymatic degradation in in vitro studies.

A dash means that the catalog does not declare that field for the compound. If neither entry declares a field, the row is omitted. A label purity specification of ≥ 99 % is not an analytical result; results must come from the certificate for the relevant batch.

Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

The bibliography brings together work on the analog with DAC and analytical studies that distinguish the two variants. PMID 34665524 includes CJC-1295 without DAC in in vitro research; it does not establish its exposure in humans. Findings for the variant with DAC do not carry over to this preparation.

Consult each product page for its current presentations, availability, batch documentation and price. This comparison does not freeze commercial information in the research text.

The compendium entries contain the extended definitions, research context and indexed bibliography for each compound. The comparison organizes declared information; it does not replace study-specific interpretation or batch identity evidence.